Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has provided an update.
Shandong Xinhua Pharmaceutical Company Limited has announced the approval of its marketing application for Vonoprazan Fumarate, a chemical active pharmaceutical ingredient used to treat reflux esophagitis. This approval, granted by the National Medical Products Administration, positions the product within China’s public medical institutions, where related sales reached approximately RMB 825 million in 2024, indicating significant market potential and impact for the company.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a pharmaceutical company based in China, primarily involved in the production and marketing of chemical drugs. The company focuses on the development of active pharmaceutical ingredients, with a market emphasis on products listed in the National Drug Catalogue for Basic Medical Insurance.
Average Trading Volume: 2,158,245
Technical Sentiment Signal: Buy
Current Market Cap: HK$10.8B
See more insights into 0719 stock on TipRanks’ Stock Analysis page.